doi,title,abstract,label_included
,,"Articles were included if they met the following criteria: (1) study involved transitioning from a TNFÎ± inhibitor (including etanercept, infliximab, and adalimumab) originator to a biosimilar, (2) the number of patients who retransitioned was reported or could be calculated, (3) the article was an original research article published in a peer-reviewed journal, (4) the article included baseline characteristics of the patients who transitioned, (5) the article was written in English, and (6) the full-text version of the article could be obtained. Only original research articles were included.",1
,,"Congress abstracts, reviews, editorials, and other opinion articles were excluded.",0
